Clinical Trial Update: Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 [Phase 2]

View source ↗

Summary

Phase 2 trial GV1001-PSP-CL2-011 in progressive supranuclear palsy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Supranuclear Palsy

Drugs mentioned

• GV1001

Snippet

Sponsor: GemVax & Kael | Conditions: Progressive Supranuclear Palsy | Phase 2 | Status: COMPLETED